Antiva Biosciences

Antiva Biosciences is a biopharmaceutical company developing novel topical therapies for the treatment of precancerous lesions caused by HPV, preventing their progression to invasive cancer. Our lead product, aimed at treating cervical neoplasia (HSIL or CIN2,3), utilizes antiviral prodrug chemistry developed by Dr. Karl Hostetler at the University of California, San Diego. Our goal is to provide a non-surgical alternative for the treatment of CIN2,3 to protect women's reproductive health, enabling self-administration at home and improving access to care in underserved communities with limited OB/GYN resources.